Clinical Trial

Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Announced positive survival data from ongoing randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancerPhase 2 topline…

1 month ago

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis

—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients…

1 month ago

Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street

Apellis received $375 million in funding at close, with ability to access an additional $100 millionMajority of initial proceeds used…

1 month ago

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

Conference Call and Webcast Today at 4:30 p.m. ETDevelopment Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive…

1 month ago

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

– Gained alignment with U.S. Food and Drug Administration (FDA) on brilaroxazine clinical trials for New Drug Application (NDA) submission…

1 month ago

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome; topline data…

1 month ago

Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting

PDAT clinical outcomes for infectious keratitis from Brazil and Mexico KNOXVILLE, TN, May 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals,…

1 month ago

ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention

ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux…

1 month ago

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase…

1 month ago

Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise

Cash runway extended into July 2025 from previously April 2025Capital raise strengthens Medigene’s financial positionLead program, MDG1015, on track for…

1 month ago